Aveanna Healthcare Holdings Inc. (AVAH)
NASDAQ (NGS) NASDAQ (NGS) Primary 
AVAH Q2 Earnings Call Highlights Higher Growth Targets
Aveanna raises its 2026 outlook and long-term growth targets as reimbursement gains and preferred payers support expansion.
Aveanna Healthcare: Q2 Earnings Report Boosts The Stock And Reinforces My Buy Rating
Aveanna Healthcare Holdings delivered strong Q2 2026 results, beating earnings and revenue estimates and significantly raising full-year EBITDA and revenue guidance. AVAH's valuation remains attractive versus peers, with the lowest forward P/E multiples and leading EBITDA margin, despite a 60% stock price gain since March. Private Duty Services drive 83% of revenues, but gross margins declined across all segments; rapid revenue growth offset margin pressure, yet this trend warrants monitoring.
Aveanna Healthcare Q2 Earnings Call Highlights
Aveanna Healthcare NASDAQ: AVAH reported higher second-quarter revenue and adjusted EBITDA, supported by growth across its three operating divisions, improved reimbursement rates, increased volumes and operational efficiencies. The company also raised its full-year outlook and updated its long-term organic growth targets for its Private Duty Services and Home Health and Hospice businesses.
Aveanna (AVAH) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Aveanna (AVAH) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Aveanna Healthcare (AVAH) Beats Q2 Earnings and Revenue Estimates
Aveanna Healthcare (AVAH) came out with quarterly earnings of $0.22 per share, beating the Zacks Consensus Estimate of $0.17 per share. This compares to earnings of $0.18 per share a year ago.
Is the Options Market Predicting a Spike in Aveanna Healthcare Stock?
Investors need to pay close attention to AVAH stock based on the movements in the options market lately.
Gear Up for Aveanna (AVAH) Q2 Earnings: Wall Street Estimates for Key Metrics
Besides Wall Street's top-and-bottom-line estimates for Aveanna (AVAH), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2026.
AVAH vs. CHE: Which Stock Should Value Investors Buy Now?
Investors interested in Medical - Outpatient and Home Healthcare stocks are likely familiar with Aveanna Healthcare (AVAH) and Chemed (CHE). But which of these two stocks presents investors with the better value opportunity right now?
Best Cheap Stocks Under $10 to Buy Now in August
Investors might want to start buying best-in-class, cheap stocks trading under $10 a share as the market soars to start August.
3 Stocks Showing Breakout Potential Ahead of August
Breakout stocks BSET, AVAH and IART are trading near 52-week highs after passing technical screens. See why they could outperform in August.
Should Value Investors Buy Aveanna Healthcare (AVAH) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Why Fast-paced Mover Aveanna (AVAH) Is a Great Choice for Value Investors
Aveanna (AVAH) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
